drugset / Trial / NCT05830500
Study of Anlotinib in Patients With Advanced Medullary Thyroid Carcinoma
Non-randomizedParallel-groupOpen-labelTreatment
Summary
This is a real world study aiming to observe the efficacy and safety of Anlotinib capsules in patients with advanced medullary thyroid carcinoma, and to summarize the treatment experience in a broad population of patients.
Timeline
- Start
- 2023-06-19
- Primary completion
- 2027-06
- Completion
- 2028-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Catequentinib | Small molecule | 12 mg | — |